Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.